Biocytogen Secures Favorable Court Ruling in Patent Dispute, Reinforcing Confidence in Its RenNano® Technology Platform
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (SSE: 688796; HKEX: 02315) has announced a significant legal victory following a first-instance civil judgment issued by the Shanghai Intellectual Property Court. The court ruled in favor of Biocytogen, determining that the company did not infringe the patent rights asserted by Harbour Antibodies BV and ordering the plaintiff to bear the costs associated with the litigation.
The ruling represents an important milestone for Biocytogen and provides a strong endorsement of the company’s commitment to technological innovation and intellectual property compliance. It also offers greater certainty to existing and prospective partners who rely on Biocytogen’s proprietary technology platforms, particularly the company’s RenNano® platform, which has become an important component of its antibody discovery and therapeutic development capabilities.
The decision is viewed as a significant development not only for Biocytogen but also for the broader biotechnology sector, where intellectual property rights play a central role in fostering innovation, supporting investment, and enabling the development of next-generation medicines.
Court Rules in Favor of Biocytogen
According to the judgment issued by the Shanghai Intellectual Property Court, Biocytogen was found not to have infringed the patent rights asserted by Harbour Antibodies BV in the case. In addition to rejecting the infringement claims, the court ordered the plaintiff to assume responsibility for the litigation expenses.
The ruling marks a favorable first-instance outcome for Biocytogen in a dispute that has drawn attention within the biotechnology industry due to the importance of antibody discovery technologies and proprietary research platforms in modern drug development.
Although first-instance judgments may be subject to further legal procedures under applicable laws, the decision provides substantial support for Biocytogen’s position regarding the independence and originality of its technology platforms.
For the company, the judgment represents an important validation of its research and development efforts and its approach to intellectual property management.
Background of the Patent Dispute
The litigation originated from claims filed by Harbour Antibodies BV, which holds an exclusive license to a Chinese invention patent identified as Patent No. ZL201210057668.0.
Harbour alleged that Biocytogen’s RenNano® platform, along with certain antibody products generated using the platform, infringed rights associated with the licensed patent in China.
The claims centered on technologies used in the discovery and development of antibody-based therapeutics, an area that has become increasingly important in the biopharmaceutical industry due to the growing role of biologics in treating cancer, autoimmune diseases, infectious diseases, and other serious medical conditions.
Biocytogen consistently maintained that its technologies were independently developed and did not violate the patent rights asserted in the lawsuit.
Following its review of the evidence and legal arguments presented by both parties, the Shanghai Intellectual Property Court ultimately agreed with Biocytogen’s position and ruled that infringement had not occurred.
Importance of Intellectual Property in Biotechnology
Intellectual property protection serves as a cornerstone of innovation in the biotechnology and pharmaceutical sectors. Companies invest significant resources into research, platform development, and drug discovery programs, often over many years, before products reach commercialization.
Patents and other forms of intellectual property protection help safeguard these investments by providing legal mechanisms that encourage innovation while supporting collaboration and technology transfer across the industry.
As competition intensifies in areas such as antibody engineering, gene editing, cell therapies, and precision medicine, intellectual property disputes have become increasingly common. Court decisions in these cases can have substantial implications for technology licensing, strategic partnerships, and future product development.
The favorable ruling for Biocytogen reinforces the company’s position that its proprietary technologies have been developed independently and in compliance with applicable intellectual property requirements.
Strengthening Confidence in the RenNano® Platform
One of the most significant implications of the court’s decision relates to Biocytogen’s RenNano® platform.
RenNano® is a proprietary antibody discovery platform designed to support the generation of fully human heavy-chain-only antibodies and VHH-based therapeutics. The technology has become an important element of the company’s broader drug discovery infrastructure and has been utilized in collaborations with pharmaceutical and biotechnology partners around the world.
The platform is intended to accelerate the discovery of novel therapeutic antibodies while enabling the development of next-generation biologics targeting a wide range of diseases.
Because intellectual property considerations often play a major role in partnership decisions, the favorable judgment provides additional reassurance for current collaborators and prospective partners evaluating the platform for future research and development initiatives.
By confirming the absence of patent infringement in this case, the ruling may help strengthen confidence in the long-term viability and commercial potential of RenNano®-enabled programs.
Broad Technology Portfolio Supports Innovation
Biocytogen has built its reputation on a diversified portfolio of proprietary technologies spanning multiple areas of biomedical research and drug development.
Over the years, the company has developed globally competitive platforms that include:
- Gene-editing technologies
- Target-humanized animal models
- Fully human antibody discovery systems
- Preclinical research services
- Therapeutic antibody development capabilities
These technologies support both the company’s internal drug development programs and a growing network of strategic collaborations with biotechnology and pharmaceutical organizations worldwide.
The company’s integrated approach allows researchers to move from target identification and validation through antibody discovery and preclinical evaluation using a unified technology ecosystem.
The RenNano® platform represents a key component of this ecosystem and continues to play an important role in the advancement of novel VHH-based therapeutic candidates.
Commitment to Intellectual Property Compliance
Biocytogen emphasized that intellectual property protection remains a fundamental principle guiding its research and business operations.
The company has consistently highlighted the importance of:
- Creating original technologies
- Protecting proprietary innovations
- Respecting the intellectual property rights of others
- Maintaining compliance with applicable legal and regulatory requirements
According to the company, these principles are essential for sustaining innovation and fostering productive collaboration across the global life sciences industry.
The favorable court decision further supports Biocytogen’s long-standing position that its technology platforms have been developed through independent scientific innovation and responsible intellectual property management practices.
Implications for Global Partnerships
As biotechnology companies increasingly rely on strategic collaborations to advance therapeutic programs, intellectual property certainty becomes a critical consideration for potential partners.
Organizations evaluating technology platforms often assess not only scientific capabilities but also the legal and intellectual property landscape surrounding those technologies.
The Shanghai Intellectual Property Court’s ruling provides additional clarity regarding the legal status of Biocytogen’s RenNano® platform and related technologies.
This increased certainty may help facilitate future collaborations by reducing perceived intellectual property risks and reinforcing confidence among pharmaceutical companies, biotechnology firms, academic institutions, and investors considering partnerships with Biocytogen.
The company believes the judgment strengthens the credibility of its technology offerings and highlights the robustness of its innovation strategy.
Supporting Future Growth and Innovation
Biocytogen views the court’s decision as an affirmation of its commitment to scientific excellence and technological advancement.
The company has continued to invest heavily in research and development, seeking to expand the capabilities of its proprietary platforms while advancing novel therapeutic candidates through preclinical and clinical development.
Looking ahead, Biocytogen plans to continue enhancing its technology infrastructure, strengthening its scientific capabilities, and expanding opportunities for collaboration across the global life sciences ecosystem.
Management believes that sustained investment in innovation will enable the company to create greater value for partners and contribute to the development of new therapies that address significant unmet medical needs.
The favorable first-instance judgment issued by the Shanghai Intellectual Property Court represents an important achievement for Biocytogen Pharmaceuticals and provides meaningful validation of the company’s independent innovation efforts. By ruling that Biocytogen did not infringe the patent rights asserted by Harbour Antibodies BV, the court has reinforced confidence in the company’s proprietary technology platforms, particularly the RenNano® antibody discovery platform.
Beyond the immediate legal outcome, the decision highlights the importance of intellectual property integrity in the biotechnology industry and underscores Biocytogen’s commitment to responsible innovation, compliance, and scientific advancement. As the company continues to expand its global collaborations and develop next-generation therapeutic technologies, the ruling is expected to strengthen confidence among partners, investors, and stakeholders while supporting Biocytogen’s long-term growth strategy and leadership in antibody discovery and drug development.
About Biocytogen
Biocytogen (SSE: 688796; HKEX: 02315) is a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies. Founded on gene editing technology, Biocytogen has established a dual-engine platform combining a fully human antibody library with an extensive target-humanized mouse model portfolio, enabling a systematic approach to accelerating global drug discovery and development.
Biocytogen has independently developed its proprietary RenMice® (RenMab®/RenLite®/RenNano®/RenTCR™/RenTCR mimic™) platforms for fully human monoclonal/bispecific/multispecific antibody discovery, bispecific antibody-drug conjugate discovery, hu-VHH discovery, and TCR mimic antibody discovery, and has established a sub-brand, RenSuper™ Biologics, to explore global partnerships for an off-the-shelf library of >1,000,000 fully human antibody sequences against over 1000 targets for worldwide collaboration.
As of December 31, 2025, more than 350 agreements for therapeutic antibodies and clinical assets—spanning co-development, out-licensing, and transfers—have been established globally, including landmark partnerships with leading multinational pharmaceutical companies (MNCs).
Biocytogen pioneered the generation of drug target knock-in humanized models for preclinical research, and currently provides a few thousand off-the-shelf animal and cell models under the company’s sub-brand, BioMice™, along with preclinical pharmacology and gene-editing services for clients worldwide. Headquartered in Beijing, Biocytogen has branches in China (Haimen, Jiangsu, Shanghai), the USA (Boston, San Francisco, San Diego), and Germany (Heidelberg).
